Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Primary Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00005836
What this trial is testing

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT03029598
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
University of Washington 29
Early research (Phase 1)Ended earlyNCT01952249
What this trial is testing

Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian

Who this might be right for
Primary Peritoneal Carcinoma
OncoMed Pharmaceuticals, Inc. 20
Early research (Phase 1)Active Not RecruitingNCT01970722
What this trial is testing

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Who this might be right for
FIGO Stage IVA Ovarian CancerFIGO Stage IVB Ovarian CancerPlatinum-Resistant Ovarian Carcinoma+26 more
City of Hope Medical Center 40
Testing effectiveness (Phase 2)Study completedNCT00022347
What this trial is testing

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT05198804
What this trial is testing

Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal Carcinoma+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 117
Large-scale testing (Phase 3)Looking for participantsNCT06994195
What this trial is testing

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 450
Testing effectiveness (Phase 2)Ended earlyNCT02900560
What this trial is testing

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
Translational Research in Oncology 34
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT02751918
What this trial is testing

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Who this might be right for
Ovarian Neoplasms
Bayer 65
Testing effectiveness (Phase 2)Ended earlyNCT02364713
What this trial is testing

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+24 more
Mayo Clinic 17
Large-scale testing (Phase 3)Study completedNCT01204749
What this trial is testing

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 919
Testing effectiveness (Phase 2)Ended earlyNCT05261490
What this trial is testing

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+3 more
Pfizer 10
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Large-scale testing (Phase 3)Study completedNCT02631876
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
ImmunoGen, Inc. 366
Early research (Phase 1)Ended earlyNCT03691376
What this trial is testing

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more
Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Large-scale testing (Phase 3)Active Not RecruitingNCT05257408
What this trial is testing

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Who this might be right for
Ovarian NeoplasmFallopian Tube NeoplasmsPeritoneal Neoplasms
Corcept Therapeutics 381
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Early research (Phase 1)Ended earlyNCT04244552
What this trial is testing

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Who this might be right for
Breast CancerColorectal CancerOvarian Cancer+13 more
Atreca, Inc. 87
Next Page